Literature DB >> 20820662

Selective inhibition of ADAR2-catalyzed editing of the serotonin 2c receptor pre-mRNA by a helix-threading peptide.

Nicole T Schirle1, Rena A Goodman, Malathy Krishnamurthy, Peter A Beal.   

Abstract

RNA editing by adenosine deamination is a form of epigenetic control of gene expression wherein the ADAR enzymes convert adenosine to inosine in RNA often changing the meaning of codons. The pre-mRNA for the 2c subtype of serotonin receptor (5-HT2cR) is shown here to support small molecule binding near known editing sites. Furthermore, a helix-threading peptide binds this site and inhibits the in vitro reaction of ADAR2 in an RNA-substrate selective manner. This is the first example of substrate-selective inhibition of editing by an RNA-binding small molecule and sets the stage for the development of new reagents capable of controlling gene function through manipulation of mRNA editing.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20820662     DOI: 10.1039/c0ob00309c

Source DB:  PubMed          Journal:  Org Biomol Chem        ISSN: 1477-0520            Impact factor:   3.876


  17 in total

1.  RNA-Seq analysis identifies a novel set of editing substrates for human ADAR2 present in Saccharomyces cerevisiae.

Authors:  Tristan Eifler; Subhash Pokharel; Peter A Beal
Journal:  Biochemistry       Date:  2013-10-31       Impact factor: 3.162

2.  Covalent stabilization of a small molecule-RNA complex.

Authors:  Hayden Peacock; Radhika Bachu; Peter A Beal
Journal:  Bioorg Med Chem Lett       Date:  2011-05-05       Impact factor: 2.823

Review 3.  The activity of the serotonin receptor 2C is regulated by alternative splicing.

Authors:  Stefan Stamm; Samuel B Gruber; Alexander G Rabchevsky; Ronald B Emeson
Journal:  Hum Genet       Date:  2017-06-29       Impact factor: 4.132

4.  RNA editing enters the limelight in cancer.

Authors:  Angela Gallo
Journal:  Nat Med       Date:  2013-02       Impact factor: 53.440

5.  Noncoding regions of C. elegans mRNA undergo selective adenosine to inosine deamination and contain a small number of editing sites per transcript.

Authors:  Emily C Wheeler; Michael C Washburn; Francois Major; Douglas B Rusch; Heather A Hundley
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

Review 6.  RNA editing-dependent epitranscriptome diversity in cancer stem cells.

Authors:  Qingfei Jiang; Leslie A Crews; Frida Holm; Catriona H M Jamieson
Journal:  Nat Rev Cancer       Date:  2017-04-18       Impact factor: 60.716

7.  Potent and selective inhibition of A-to-I RNA editing with 2'-O-methyl/locked nucleic acid-containing antisense oligoribonucleotides.

Authors:  Rena A Mizrahi; Nicole T Schirle; Peter A Beal
Journal:  ACS Chem Biol       Date:  2013-02-21       Impact factor: 5.100

8.  A screening protocol for identification of functional mutants of RNA editing adenosine deaminases.

Authors:  Tristan Eifler; Dalen Chan; Peter A Beal
Journal:  Curr Protoc Chem Biol       Date:  2012-12-01

Review 9.  Epitranscriptomic Modifications Modulate Normal and Pathological Functions in CNS.

Authors:  Anil K Chokkalla; Suresh L Mehta; Raghu Vemuganti
Journal:  Transl Stroke Res       Date:  2021-07-05       Impact factor: 6.829

10.  Nucleoside analog studies indicate mechanistic differences between RNA-editing adenosine deaminases.

Authors:  Rena A Mizrahi; Kelly J Phelps; Andrea Y Ching; Peter A Beal
Journal:  Nucleic Acids Res       Date:  2012-08-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.